Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 11 of 58, showing 10 Applications out of 576 total, starting on record 101, ending on 110

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

101.

ECCT/24/06/02   ALNASA
    A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE   
Principal Investigator(s)
1. Jesse Gitaka
Site(s) in Kenya
1. Center for Research In Tropical Medicine and Community Development (Nairobi City county)
2. Clinical Research Health Network (CREA-N) (Machakos county)
3. KEMRI-Mtwapa Clinical Annex (Kilifi county)
4. University of Nairobi Clinical Research Centre (Nairobi City county)
5. KEMRI-CRDR Clinical Research Annex (Nairobi City county)
 
25-11-2024 View

102.

ECCT/24/07/01   LCCC 2330
    Feasibility of intravaginal artesunate as adjuvant HPV & cervical precancer treatment among women living with HIV in Kenya: A Phase II trial   
Principal Investigator(s)
1. Chemtai Mungo
Site(s) in Kenya
Cervical Cancer Screening Program (CCSP) Lumumba Sub-County Hospital
 
25-11-2024 View

103.

ECCT/24/09/02   ALNASA
    A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE   
Principal Investigator(s)
1. Teresa Kinyari
Site(s) in Kenya
1. University of Nairobi Clinical Research Centre (Nairobi City county)
2. KEMRI-Mtwapa Clinical Annex (Kilifi county)
3. Center for Research In Tropical Medicine and Community Development (Nairobi City county)
4. Clinical Research Health Network (CREA-N) (Machakos county)
5. KEMRI-CRDR Clinical Research Annex (Nairobi City county)
 
13-11-2024 View

104.

ECCT/24/10/02   Gates MRI TBV02-301
    A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults.   
Principal Investigator(s)
1. Dr Isaac Tsikhutsu
Site(s) in Kenya
1. Kenya Medical Research Institute/Walter Reed Project, Clinical Research Center (Kericho county)
 
12-11-2024 View

105.

ECCT/24/06/04   ALNASA
    A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE       
Principal Investigator(s)
1. Jacqueline Mirera
Site(s) in Kenya
1. Clinical Research Health Network (CREA-N) (Machakos county)
 
23-10-2024 View

106.

ECCT/24/08/01   Evaluate clearance of HPV
    A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts   
Principal Investigator(s)
1. Fredrick Chite Asirwa
2. Kevin Makori Gesimba
Site(s) in Kenya
1. International Cancer Institute (ICI) (Uasin Gishu county)
2. Victoria Cancer Care and Research centre (Nyamira county)
 
16-10-2024 View

107.

ECCT/24/06/03   PEARL RSVt Vaccine Study
    Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL   
Principal Investigator(s)
1. Dr Walter Otieno
Site(s) in Kenya
1. KEMRI-USAMRD-A Kombewa Clinical Research Centre (Kisumu county)
 
20-09-2024 View

108.

ECCT/24/02/05   Doxo-study
    Pharmacokinetic profiles for Doxorubicin among children with childhood cancer in Kenya.           
Principal Investigator(s)
1. Festus MUIGAI Njunguna
Site(s) in Kenya
MOI UNIVERSITY SCHOOL OF MEDICINE
 
20-09-2024 View

109.

ECCT/24/04/04   TNBC
    A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF TOBEMSTOMIG/RO7247669 COMBINED WITH NAB-PACLITAXEL COMPARED WITH   PEMBROLIZUMAB COMBINED WITH NABPACLITAXEL IN PARTICIPANTS WITH PREVIOUSLY UNTREATED, PD-L1-POSITIVE, LOCALLY-ADVANCED UNRESECTABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER   
Principal Investigator(s)
1. Mansoor Saleh
Site(s) in Kenya
1. University of Nairobi - Institute of Tropical and Infectious Diseases (Nairobi City county)
2. International Cancer Institute (Nandi county)
3. The Aga Khan University Hospital - Kenya (Nairobi City county)
 
19-09-2024 View

110.

ECCT/24/04/05   Phase III Vitiligo Study
                                                                             A Double-Arm, Open Label, Phase III Study to Compare the                                           Efficacy and Safety of SCENESSE® and Narrow-Band Ultraviolet B (NB-UVB) Light versus NB-                                                                                    UVB Light Alone in the Treatment of Vitiligo   
Principal Investigator(s)
1. Dr. Hannah Wanyika Wanyika
Site(s) in Kenya
Kenyatta National Hospital -
 
30-08-2024 View